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Abstract
Purpose: This study was aimed to increase the quality of high dose rate (HDR)intraluminal brachytherapy treatment. For this purpose, an easy, fast and accuratepatient-specific quality assurance (QA) tool has been developed. This tool has beenimplemented at Bahawalpur Institute of Nuclear Medicine and Oncology (BINO),Bahawalpur, Pakistan. Methods: ABACUS 3.1 Treatment planning system (TPS)has been used for treatment planning and calculation of total dwell time and thenresults were compared with the time calculated using the proposed method. Thismethod has been used to verify the total dwell time for different rectum applicatorsfor relevant treatment lengths (2-7 cm) and depths (1.5-2.5 cm), differentoesophagus applicators of relevant treatment lengths (6-10 cm) and depths (0.9 &1.0 cm), and a bronchus applicator for relevant treatment lengths (4-7.5 cm) anddepth (0.5 cm). Results: The average percentage differences between treatmenttime TMwith manual calculation and as calculated by the TPS is 0.32% (standarddeviation 1.32%) for rectum, 0.24% (standard deviation 2.36%) for oesophagusand 1.96% (standard deviation 0.55%) for bronchus, respectively. These resultsadvocate that the proposed method is valuable for independent verification ofpatient-specific treatment planning QA. Conclusion: The technique illustrated inthe current study is an easy, simple, quick and useful for independent verificationof the total dwell time for HDR intraluminal brachytherapy. Our method is able toidentify human error-related planning mistakes and to evaluate the quality oftreatment planning. It enhances the quality of brachytherapy treatment andreliability of the system.
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1. IntroductionThe plan is to enhance the quality of intraluminalbrachytherapy treatment. For this purpose, independentverification of total dwell time for individual patient isneeded. The aim of current investigation is to develop aneasy, accurate, simple and independent verificationmethod for the authentication of treatment time oftreatment planning system (TPS).Brachytherapy is a vital part of radiotherapy for themalignancies of intralumen and is frequently used withexternal beam radiation therapy (EBRT) forradical/palliative treatment. Several studies have
suggested that control rates are considerably enhancedwith EBRT and brachytherapy1-4. High dose rate (HDR)remote after loading intraluminal brachytherapy hasbeen commonly used all over the world4. Thesignificance of independent verification of dosimetryearlier to HDR brachytherapy treatment delivery hasbeen acknowledged universally. Thomadsen et al.recognized 44 errors in HDR brachytherapy treatmentin data (1980-2001) from the Nuclear RegulatoryCommission and International Atomic Energy Agency5Guidelines6,7 recommended the independentconfirmation about the procedures for a pre-treatment
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review of the treatment planning system and thecomputer algorithms employed to calculate the dosedistributions across the planning target volume (PTV).Techniques are required to be put into practice in orderto reduce systematic and random errors in planning andtreatment procedures as well. The input to treatmentplanning system can be provided with multimodalityimages (i.e. CT/MRI/Orthogonal X-rays/Ultrasound) andthis software, enabled the medical physicists tomaximize the dose uniformity, whilst minimizing theimplant volume required to cover the target volumesufficiently as well as lessens the dose to the organs atrisk. Such flexibility makes a challenge for the medicalphysicists for the confirmation of the optimizedtreatment time with manual calculation technique,which takes only a few minutes while providing a highprobability of noticing considerable mistakes/errors.Actually, patients are often have to wait for the durationof treatment planning with an applicator introduced by aradiation oncologist and there is a huge amount of timepressure on the planning procedure. During that time,errors/mistakes and miscommunications may easilyhappened. To detect these errors, the need ofpatient-specific QA as well as independent verification ofthe key treatment planning parameter (i.e. time) areobvious and have to be performed rapidly and easily toensure the safety and accuracy of the treatment.The literature has reported independent authenticationtechniques for external beam radiation therapy8 andHDR brachytherapy treatment planning. A number oftechniques for inspection of a brachytherapy treatmentplan were reported. Various methods check onsingle-implant9-12 or double- implants13, 14. Some verifyintracavitary gynecological treatments11, 12, 15, 16, volumeimplants17-21 and endobronchial brachytherapy13, 14.Recently many investigators have developed in-housesoftware to compute the dose at arbitrary points 22-24.Such software may be helpful for the commissioning ofTPS, in medical practice, human errors in individualtreatment planning in radiotherapy will not berecognized because of the use of the similar coordinatesystem, digitized applicator paths and dose pointcoordinates as those in the treatment planning system.Although sufficient literature is available for verificationof treatment planning time but only few studies13, 14 areavailable for bronchus brachytherapy and no literatureregarding rectum and oesophagus was found. It wasaimed to introduce intraluminal (oesophagus, bronchusand rectum) brachytherapy in our institute. This paperpresents a very quick, simple and easy patient-specificindependent verification method of the treatment time(sum of all dwell times) for intraluminal brachytherapyapplicators. The time needed for confirmation is in theorder of 10-15 seconds if an Excel spreadsheet isavailable otherwise 1-2 minutes, despite the nature ofapplicator. A negligible additional waiting time for the
patient is needed for this verification process but itprovides a valuable independent confirmation.
2. Methods and MaterialsBahawalpur Institute of Nuclear Medicine and Oncologyhas started radiotherapy in 1998 and HDRbrachytherapy was made available in October 2004.Gynecological and surface malignancies are beingtreated with brachytherapy. It was intended to extendour services to other sites i.e. rectum, oesophagus andbronchus. For this purpose, authentication of treatmenttime as calculated by TPS is needed.ABACUS 3.1 TPS, manufactured by Varian MedicalSolutions, USA is used for the current investigations. Themethod proposed here is therefore intended toharmonize with the ABACUS 3.1 (but it is equallyapplicable to other TPS, like Plato TPS etc. and off courseuniversal in nature). All dosimetric calculations wereperformed for a nominal 37 GBq (10 Ci) source strengthand 7 Gy as prescribed doses; it can be used for othersource strengths and prescribed doses. ABACUS 3.1 hasbeen used for treatment planning and calculation of totalnominal time first and then results were compared withproposed method. Treatment planning for intraluminal(oesophagus, bronchus and rectum) brachytherapyusing different available applicators was aimed to beverified with the manual planning. The factors requiredfor the calculation are the prescribed dose, the depth ofdose prescription, the length of dose prescription andsource strength.Dose delivery time was calculated manually with theequation;= ( )∗( )∗( / )∗( / )∗( )∗( / )∗ (1)This equation was derived from Johns et al. 25 by usinglong and away tables and converted to Iridium based onthe exposure rate constant, which indicated that themanual calculation of time requires some values asinput. These values i.e. RL and elongation factor havebeen derived from Johns et al.25 using Table 13.3 andFigure 13.5. The RL is the mg.hr to deliver 1000 rads to apoint h cm from the center of a linear source of activelength L. From Table 13.325, find the value of length infirst column and then go right in the corresponding row,where it intersects the corresponding treatmentdistance that value is for RL. The elongation factor hasbeen determined by taking the ratio of the length oftreatment/ distance of treatment (ratio of L/h). Thenusing Figure 13.525 (that looks like a Gaussian curve atthe bottom of the page) ratio of L/h vs percent increaseis obtained and go straight up on the graph, and lookacross for the percent increase in the value. Then thevalue we get, suppose it was 16 on the y-axis, theelongation factor is going to be 1.16 because it is apercentage increase of dose due to lateral scatter, andcontribution from surrounding sources. The conversion
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factor from Radium-226 to Iridium-192 is mg/mCi =0.5648. The applicators available at XINO for rectum,esophagus and bronchus manufactured by VarianMedical Solution, USA and are compatible with GammaMed plus HDR unit and ABACUS 3.1 TPS have been usedfor this study as shown in Figure 1. MS Excels, SPSS 16.0have been used for data analysis. EndNote 5 has beenused for reference management.
Figure 1: Different applicators for rectum, esophagus andbronchus.
2.1 Method’s evaluationTo evaluate the proposed method for clinical use andvalidation of TPS for intraluminal applications, it wasused to verify the total dwell time for three differentdiameters (2, 3 and 4 cm) rectum applicators for clinicalrelevant treatment lengths (2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0,5.5, 6.0, 6.5, and 7.0 cm) and treatment depths (1.5, 2.0,and 2.5), three different diameters (8, 10 and 12 mm)oesophagus applicators for clinical relevant treatmentlengths (6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 and 10.0 cm)and treatment depths (0.9 and 1.0 cm), and one (5 mmdiameter) bronchus applicator for clinical relevanttreatment lengths (4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0 and 7.5cm) and treatment depth (0.5 cm) are available atBINOXINO.
3. ResultsThe objective was to confirm the total nominal timecalculated by means of ABACUS TPS with the help ofmanual method, for different treatment lengths andtreatment depths by developing and implementing a fastand accurate secondary dose calculation technique forQA of HDR treatment planning. For 10 Ci activity ofIridium-192 and 0.5648 conversion factor (Radium toIridium), the treatment time comparison for different
applicators available for rectum, esophagus andbronchus as well as percentage difference between theresults of both methods for different diameters,treatment depths and lengths have been calculated andresults are presented in the tables 1-3. The averagepercentage difference between treatment time TM withmanual calculation and as calculated by the TPS was0.32% (standard deviation 1.32%) for rectum, 0.24%(standard deviation 2.36%) for oesophagus and 1.96%(standard deviation 0.55%) for bronchus, respectively.Comparison between the treatment times as calculatedby TPS and manual method for different rectum,oesophagus and bronchus applicators are graphicallydepicted in figures 2-4 respectively.
Figure 2: Comparison between the treatment times ascalculated by TPS and manual method for different rectumapplicators.
Figure 3: Comparison between the treatment times ascalculated by TPS and manual method for differentesophagus applicators.
Figure 4: Comparison between the treatment times ascalculated by TPS and manual method for differentbronchus applicators.
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Table 1: Percentage difference between total nominal time calculated by the manual method and Abacus 3.1 for availablerectum applicators.TreatmentLengthL (cm) RatioL/h ElongationFactor RL Prescribeddose (Gy) TM(see) TTPS(See) %Difference2.0 cm dia Rectum applicator, 1.5 cm Treatment height (depth)2.0 1.33 1.110 320.0 7.0 158.48 163 -2.852.5 1.67 1.130 340.0 7.0 171.42 176 -2.673.0 2.00 1.145 365.0 7.0 186.47 190 -1.893.5 2.33 1.170 391.0 7.0 204.11 203 0.544.0 2.67 1.180 417.0 7.0 219.55 217 1.164.5 3.00 1.180 444.0 7.0 233.76 231 1.185.0 3.33 1.180 471.0 7.0 247.98 246 0.805.5 3.67 1.170 500.5 7.0 261.27 260 0.496.0 4.00 1.160 530.0 7.0 274.31 274 0.116.5 4.33 1.160 559.0 7.0 289.32 288 0.467.0 4.67 1.150 588.0 7.0 301.70 303 -0.433.0 cm dia Rectum applicator, 2.0 cm Treatment height (depth)2.0 1.00 1.085 546.0 7.0 264.32 265 -0.262.5 1.25 1.100 569.0 7.0 279.26 281 -0.623.0 1.50 1.120 594.0 7.0 296.83 298 -0.393.5 1.75 1.130 620.0 7.0 312.59 315 -0.774.0 2.00 1.135 650.0 7.0 329.17 333 -1.164.5 2.25 1.150 684.0 7.0 350.96 351 -0.015.0 2.50 1.165 718.0 7.0 373.21 369 1.135.5 2.75 1.170 752.0 7.0 392.56 388 1.166.0 3.00 1.180 789.0 7.0 415.40 406 2.266.5 3.25 1.180 826.0 7.0 434.88 426 2.047.0 3.50 1.175 864.0 7.0 452.96 445 1.764.0 cm dia Rectum applicator, 2.5 cm Treatment height (depth)2.0 0.80 1.080 830.0 7.0 399.95 393 1.742.5 1.00 1.085 851.0 7.0 411.97 411 0.243.0 1.20 1.100 877.0 7.0 430.43 431 -0.133.5 1.40 1.110 905.0 7.0 448.21 451 -0.624.0 1.60 1.122 943.0 7.0 472.07 472 0.024.5 1.80 1.130 980.0 7.0 494.09 494 0.025.0 2.00 1.135 1018.0 7.0 515.52 516 -0.095.5 2.20 1.150 1060.0 7.0 543.89 539 0.906.0 2.40 1.160 1101.0 7.0 569.84 561 1.556.5 2.60 1.170 1145.0 7.0 597.72 585 2.137.0 2.80 1.180 1189.0 7.0 625.99 609 2.71
Table 2: Percentage difference between total nominal time calculated by the manual method and Abacus 3.1 for availablebronchus applicator.TreatmentLength L (cm) RatioL/h Elongationfactor RL Prescribeddose (Gy) TM(see) TTPS(See) %Difference5 mm dia Bronchial applicator, 0.75 cm Treatment height (depth)4.0 5.33 1.145 163.0 7.0 83.27 85 -2.084.5 6.00 1.130 179.0 7.0 90.25 92 -1.945.0 6.67 1.110 195.0 7.0 96.57 99 -2.515.5 7.33 1.095 212.0 7.0 103.58 106 -2.346.0 8.00 1.095 228.0 7.0 111.39 113 -1.446.5 8.67 1.090 244.0 7.0 118.66 121 -1.977.0 9.33 1.085 260.0 7.0 125.87 127 -0.907.5 10.00 1.070 276.0 7.0 131.76 135 -2.46
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Table 2: Percentage difference between total nominal time calculated by the manual method and Abacus 3.1 for availableesophagus applicators.T. LengthL (cm) RatioL/h Elongationfactor RL Prescribeddose (Gy) TM(see) TTPS(See) %Difference8 mm dia Esophagus applicator, 0.9 cm Treatment height (depth)6.0 6.67 1.110 316.0 7.0 156.50 152 2.886.5 7.22 1.095 338.0 7.0 165.13 159 3.717.0 7.78 1.090 359.0 7.0 174.59 169 3.207.5 8.33 1.088 382.0 7.0 185.44 180 2.938.0 8.89 1.085 404.0 7.0 195.58 188 3.878.5 9.44 1.082 426.0 7.0 205.66 198 3.729.0 10.00 1.070 448.0 7.0 213.88 206 3.6810 mm dia Esophagus applicator, 1.0 cm Treatment height (depth)6.0 6.0 1.130 316.0 7.0 159.32 162 -1.686.5 6.5 1.120 338.0 7.0 168.90 172 -1.837.0 7.0 1.110 359.0 7.0 177.80 182 -2.367.5 7.5 1.100 382.0 7.0 187.48 191 -1.888.0 8.0 1.095 404.0 7.0 197.38 200 -1.338.5 8.5 1.090 426.0 7.0 207.18 210 -1.369.0 9.0 1.085 448.0 7.0 216.88 220 -1.449.5 9.5 1.08 470.0 7.0 226.48 230 -1.5510.0 10.0 1.07 493.0 7.0 235.36 239 -1.5512 mm dia Esophagus applicator, 1.0 cm Treatment height (depth)6.0 6.00 1.130 316.0 7.0 159.32 162 -1.686.5 6.50 1.120 338.0 7.0 168.90 172 -1.837.0 7.00 1.110 359.0 7.0 177.80 182 -2.367.5 7.50 1.100 382.0 7.0 187.48 191 -1.888.0 8.00 1.095 404.0 7.0 197.38 200 -1.338.5 8.50 1.090 426.0 7.0 207.18 210 -1.369.0 9.00 1.085 448.0 7.0 216.88 220 -1.449.5 9.50 1.08 470.0 7.0 226.48 230 -1.5510.0 10.00 1.07 493.0 7.0 235.36 239 -1.55
4. DiscussionThe results of the proposed method are in reasonablygood agreement with previously published work9. In theliterature, the reported correctness of manuallycalculated treatment time vary from 1% (one singlecatheter9) through 5% (volume implant20) up to 10%(planar implants19). The results of the present study arecomparable to the literature9.The figures 2-4 show that the treatment time ascalculated by both techniques is closely matched.Treatment time was increased with the increase intreatment length or depth or both.The technique illustrated in the current study is asimple, quick and useful for HDR intraluminalbrachytherapy (rectum, esophagus and bronchus) thatneeds no particular expertise for example developingTG43-based in-house software to verify the dosecalculation i.e. the total treatment time to deliver theprescribed dose earlier to each treatment. It requiresapproximately one minute and hence does notconsiderably lengthen the patient’s waiting time. Thekey usefulness of the second check philosophy employedin the present investigation is to gain confidence that thedose calculation is correct. Although the accurateness of
dose computations is completely confirmed uponcommissioning and during periodic quality assurancetests, checking the dose delivery time prior to eachtreatment guarantees that the correct treatment depth,treatment length, prescribe dose and the correct activity(source strength) are being used and that any bug(known or unknown) in the planning software did notaffect the dose calculation.Treatment planning is a complex as well as a time takingprocess in radiotherapy in general and in brachytherapyin particular that includes the applicator insertion, acomplex simulation, CT/MRI or Orthogonal radiograph,transfer of simulation data to treatment planning systemand then the best possible treatment plan for anindividual patient. Each step is prone to one or moresources of error, so it is essential to be performed withthe greatest accuracy achievable. The ambiguity in eachstep may influence the accuracy of subsequent stepsand, therefore can have an impact on the overalltreatment time. Confirmation of the total dwell time byan independent method certainly ensures the accuracy,reliability and authenticity of all component processes.Despite its great simplicity, our method is capable toidentify human error-related planning mistakes, and toevaluate the quality of treatment planning. Numerous
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other independent confirmation techniques forindividual treatment planning have been presented.Kumar et al. presented an in-house method, whichcalculates the dose at arbitral points22. Lachaine et al.also presented an in-house technique, which completesvery quick calculation of point dose23. Such kinds oftechniques are probably to be valuable in thecommissioning of treatment planning systems andpartially in individual treatment planning QA too.Though, since these methods make use of the sameCartesian coordinate system, digitized applicator pathsand dose point coordinates as in the treatment planningsystem, they are incapable to notice human errorsrelated with the treatment planning process, forinstance set of prescription point with the incorrectcoordinate, the wrong digitization of applicators,erroneous dose points or applicator points,inappropriate magnification of simulation films, orutilization of an unintended size or arrangement ofapplicators.
5. ConclusionVerification of the accuracy of optimized calculationswith confirmation, evaluation method is fundamental inorder to guarantee the quality of treatment. Thisindependent verification tool for confirmation of thetotal dwell time in TPS plan of intraluminal HDRbrachytherapy presents a solid base to apply the plan forbrachytherapy treatment. The average percentagedifferences between treatment time TM with manualcalculations and as calculated by the TPS is 0.32%(standard deviation 1.32%) for rectum, 0.24% (standarddeviation 2.36%) for esophagus and 1.96% (standarddeviation 0.55%) for bronchus, respectively. Theseresults advocate that the proposed method is valuablefor independent verification of patient-specifictreatment planning QA. In conclusion, we havedeveloped a very simple, trouble-free, fast andindependent verification technique for intraluminalbrachytherapy. It enhances the quality of brachytherapytreatment and reliability of the system.
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